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Vibrio vulnificus is a heterogeneous bacterial species that comprises virulent and avirulent strains from
environmental and clinical sources that have been grouped into three biotypes. To validate the typing methods
proposed to distinguish clinical from environmental isolates, we performed phenotypic (API 20E, API 20NE,
and BIOLOG tests) and genetic (ribotyping and DNA polymorphism at several loci) studies with a large strain
collection representing different biotypes, origins, and host ranges. No phenotypic method was useful for
biotyping or grouping strains with regard to the origin of an isolate, and only the BIOLOG system was reliable
for identifying the strains at the species level. DNA polymorphisms divided the population into three major
profiles. Profile 1 strains were vcg type C, 16S rRNA type B, and vvh type 1 and included most of the biotype
1 human septicemic isolates; profile 2 strains were vcg type E, 16S rRNA type A, and vvh type 2 and included
all biotype 2 isolates together with biotype 1 isolates from fish and water and some human isolates; and profile
3 strains were vcg type E, 16S rRNA type AB, and vvh type 2 and included biotype 3 strains. Ribotyping divided
the species into two groups: one group that included profile 1 biotype 1 isolates and one group that included
isolates of all three biotypes with the three profiles described above. In conclusion, no genotyping system was
able to distinguish either clinical strains from environmental strains or biogroups within the species V.
vulnificus, which suggests that new typing methodologies useful for public health have to be developed for this
species.
Vibrio vulnificus is an aquatic bacterial species that produces
infections in fish and humans (30, 31, 36). Although human
infections are relatively uncommon, they can be life threaten-
ing in patients with chronic or immunocompromising diseases
(32, 36). The main transmission routes of human vibriosis are
consumption of raw or undercooked shellfish and exposure of
open wounds or sores to seawater (32, 36). The mortality rate
due to primary septicemia after contaminated shellfish con-
sumption is approximately 50%, and the mortality rate result-
ing from reported wound infections is 25% (4, 20).
This species is phenotypically and serologically heteroge-
neous (9, 17, 38). Originally, it was divided into two biotypes,
one virulent for humans and one virulent for fish (38). In early
studies, negative results for indole production, ornithine de-
carboxylase activity, acid production from mannitol and sorbi-
tol, and growth at 42°C, as well as serological specificity, al-
lowed investigators to distinguish the first fish isolates (biotype
2 serovar E) from human isolates (9, 38). However, this simple
scheme of intraspecific classification lost its utility when more
strains were isolated from fish vibriosis worldwide (19, 21, 24).
These new isolates differed serologically and phenotypically
from the isolates initially studied (21, 24) and were grouped in
two additional serovars (serovars A and I) using the same
serotyping system (21; C. Amaro, unpublished results). Inter-
estingly, biotype 2 serovar E was also isolated from human
infections, usually after manipulation of diseased fish, which
increased the diversity of isolates able to infect humans (1). In
addition to this biotype 2 heterogeneity, a third biotype was
described in 1999 in Israel (11). To date, this biotype includes
only isolates from wound infections initiated by handling spiny
fish (11, 16). These isolates were immunologically identical to
each other but distinguishable from biotype 2 serovars using
the same serotyping system (12). At least four additional se-
rovars can be found using this serotyping system among bio-
type 1 isolates, although they have not been fully characterized
(2; C. Amaro, unpublished data).
Due to the public health importance of this species and
the difficulties in rapidly differentiating the strains with hu-
man virulence potential, several typing systems have been
developed. The main genotyping systems are based on dif-
ferences in the sequences of some loci, such as 16S rRNA,
hemolysin (vvhA) genes, or the vcg (virulence-correlated
gene) locus, which divide V. vulnificus populations in two
genotypes, one primarily associated with environmental iso-
lates and the other primarily associated with clinical isolates
(7, 28, 33, 35). Most of the typing techniques described have
been used for V. vulnificus, including randomly amplified
polymorphic DNA analysis, repetitive extragenic palin-
dromic PCR, and ribotyping, among others (5, 15, 23, 37,
39). These techniques are able to distinguish some specific
groups within V. vulnificus; however, the majority of studies
were performed with strain collections biased toward bio-
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TABLE 1. Strains used in this study and some of their properties
Strain Origin
Country and
year of
isolation
Biotype Multiplexa
DNA polymorphismb
Ribogroup
(Rt)cvcg
type
vvhA
type
16S
rRNA
type
Profile
CECT 4869 Diseased eel Belgium, 1990 1 BT1/3 E 2 A 2 AI (1)
CG106 Oyster Taiwan, 1993 1 BT1/3 C 1 B 1 AI (2)
CECT 5168 Human blood United States 1 BT1/3 C 1 B 1 AI (3)
N87 Human blood Japan, 1987 1 BT1/3 C 1 B 1 AI (3)
YJ106 Human blood Taiwan 1 BT1/3 C 1 B 1 AI (3)
CECT 5167 Human blood Japan 1 BT1/3 C 1 B 1 AI (4)
MLT 362 Oyster United States 1 BT1/3 C 1 B 1 AI (5)
VV 425 Oyster United States 1 BT1/3 E 1 A Atypical AI (6)
ATCC 33816 Human blood United States 1 BT1/3 C 1 B 1 AI (7)
CG110 Seawater Taiwan, 1993 1 BT1/3 C 1 B 1 AI (7)
CG118 Seawater Taiwan, 1993 1 BT1/3 C 1 B 1 AI (8)
E4 Oyster United States 1 BT1/3 C 1 B 1 AI (9)
CG111 Seawater Taiwan, 1993 1 BT1/3 C 1 B 1 AI (10)
MLT 364 Oyster United States 1 BT1/3 C 1 B 1 AI (11)
VV 1003 Oyster United States 1 BT1/3 C 1 B 1 AI (11)
95-8-7 Diseased eel Denmark, 1995 2 BT2-nonSerE E 2 A 2 AI (11)
CS9133 Human blood South Korea 1 BT1/3 C 1 B 1 AI (12)
CECT 4608 Eel farm water Spain, 1990 1 BT1/3 C 1 B 1 AII (13)
KH03 Human blood Japan, 2003 1 BT1/3 C 1 B 1 AII (14)
CECT 4862 Diseased eel Japan, 1979 2 BT2-SerE E 2 A 2 AII (14)
CECT 5164 Human blood United States 1 BT1/3 C 2 B Atypical AII (15)
Riu-3 Seawater Spain, 2003 1 BT1/3 E 2 A 2 AII (16)
Riu-1 Seawater Spain, 2003 1 BT1/3 E 2 AB Atypical AII (16)
94385 Leg wound Spain, 2001 1 BT1/3 E 2 B Atypical AII (17)
V4 Human blood Australia 1 BT1/3 C 1 B 1 AII (18)
PD-2-52 Eel tank water Spain, 2003 2 BT2-nonSerE E 2 A 2 BI (19)
PD-2-58 Eel tank water Spain, 2003 2 BT2-nonSerE E 2 A 2 BI (20)
CECT 4917 Diseased eel Spain, 1997 2 BT2-SerE E 2 A 2 BI (21)
CECT 4998 Diseased eel Spain, 1997 2 BT2-SerE E 2 A 2 BI (21)
JE Oyster United States 1 BT1/3 E 2 B Atypical BI (21)
CECT 5165 Seawater United States 1 BT1/3 E 2 A 2 BI (22)
A2 Diseased eel Spain, 2000 1 BT1/3 E 2 A 2 BI (23)
An4 Diseased eel Spain, 2000 1 BT1/3 E 2 A 2 BI (23)
An5 Diseased eel Spain, 2000 1 BT1/3 E 2 A 2 BI (23)
An6 Diseased eel Spain, 2000 1 BT1/3 E 2 A 2 BI (23)
CECT 4606 Eel tank water Spain, 1990 1 BT1/3 E 2 A 2 BI (23)
PD-1 Eel tank water Spain, 2001 1 BT1/3 E 2 A 2 BI (23)
PD-12 Eel tank water Spain, 2001 1 BT1/3 E 2 A 2 BI (23)
PD-3 Eel tank water Spain, 2001 1 BT1/3 E 2 A 2 BI (23)
PD-5 Eel tank water Spain, 2001 1 BT1/3 E 2 A 2 BI (23)
V1 Eel tank water Spain, 2001 1 BT1/3 E 2 A 2 BI (23)
CECT 4605 Diseased eel Spain, 1990 2 BT2-SerE E 2 A 2 BI (23)
11028 Human disease Israel, 1996 3 BT1/3 E 1 AB 3 BI (24)
162 Human disease Israel, 1997 3 BT1/3 E 1 AB 3 BI (24)
97 Human disease Israel, 1997 3 BT1/3 E 1 AB 3 BI (24)
vv12 Human disease Israel, 1996 3 BT1/3 E 1 AB 3 BI (24)
vv32 Human disease Israel 3 BT1/3 E 1 AB 3 BI (24)
CECT 5169 Human blood United States 1 BT1/3 C 1 B 1 BII (25)
94-9-119 Human disease Denmark, 1994 1 BT1/3 E 2 A 2 BII (25)
CECT 4867 Unknown Unknown 1 BT1/3 E 2 A 2 BII (25)
YN03 Human blood Japan, 2003 1 BT1/3 E 2 A 2 BII (25)
535 Diseased eel Sweden 2 BT2-nonSerE E 2 A 2 BII (25)
536 Diseased eel Sweden 2 BT2-nonSerE E 2 A 2 BII (25)
960426-1/4C Diseased eel Denmark, 1996 2 BT2-nonSerE E 2 A 2 BII (25)
960717-1/2F Diseased eel Denmark, 1996 2 BT2-nonSerE E 2 A 2 BII (25)
A10 Diseased eel Spain, 2002 2 BT2-nonSerE E 2 A 2 BII (25)
A11 Diseased eel Spain, 2002 2 BT2-nonSerE E 2 A 2 BII (25)
A13 Diseased eel Spain, 2002 2 BT2-nonSerE E 2 A 2 BII (25)
A14 Diseased eel Spain, 2002 2 BT2-nonSerE E 2 A 2 BII (25)
CECT 5198 Diseased eel Spain, 1999 2 BT2-nonSerE E 2 A 2 BII (25)
CECT 5689 Diseased eel Spain, 2002 2 BT2-nonSerE E 2 A 2 BII (25)
CECT 5768 Diseased eel Spain, 2001 2 BT2-nonSerE E 2 A 2 BII (25)
CECT 5769 Diseased eel Spain, 2002 2 BT2-nonSerE E 2 A 2 BII (25)
90-2-11 Diseased eel Denmark, 1990 2 BT2-SerE E 2 A 2 BII (25)
94-8-112 Wound infection Denmark, 1994 2 BT2-SerE E 2 A 2 BII (25)
94-9-123 Seawater Denmark, 1994 2 BT2-SerE E 2 A 2 BII (25)
C1 Healthy eel Spain, 2003 2 BT2-SerE E 2 A 2 BII (25)
CECT 4602 Diseased eel Spain, 1990 2 BT2-SerE E 2 A 2 BII (25)
CECT 4603 Diseased eel Spain, 1990 2 BT2-SerE E 2 A 2 BII (25)
CECT 4604 Diseased eel Spain, 1990 2 BT2-SerE E 2 A 2 BII (25)
CECT 4864 Diseased eel Spain, 1994 2 BT2-SerE E 2 A 2 BII (25)
CECT 4868 Diseased eel Norway, 1990 2 BT2-SerE E 2 A 2 BII (25)
CECT 4870 Diseased eel Sweden, 1991 2 BT2-SerE E 2 A 2 BII (25)
CECT 5762 Healthy eel Spain, 2002 2 BT2-SerE E 2 A 2 BII (25)
CECT 898 Diseased eel Japan, 1979 2 BT2-SerE E 2 A 2 BII (25)
CIP 81.90 Human blood France, 1981 2 BT2-SerE E 2 A 2 BII (25)
Continued on following page
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type 1, since they included few or no biotype 2 and 3 strains,
and toward North America, since the majority of the isolates
were from that geographical region (14, 37).
The main objective of our study was to validate the useful-
ness of two typing methodologies (ribotyping and polymor-
phisms at selected loci) with a wide collection of strains of the
different biotypes from different sources and geographic re-
gions, whose biochemical diversity was also analyzed by differ-
ent methodologies (API 20E, API 20NE, and BIOLOG).
MATERIALS AND METHODS
Bacterial strains and growth conditions. A total of 111 V. vulnificus strains of
different biotypes from different sources and regions were used in this study
(Table 1). The strains were maintained both as lyophilized stocks at room
temperature (25°C) and as frozen stocks at 80°C in marine broth (Difco) plus
20% (vol/vol) glycerol. Strains were grown in Luria-Bertani broth or on Luria-
Bertani agar containing 1% (wt/vol) (total concentration) NaCl at 28°C for 24 h.
Phenotypic analysis. (i) Biotyping. The biotypes of the strains were confirmed
by multiplex PCR (34). This method allows identification at the species level and
at the same time discrimination between biotypes 1/3 and 2 and, within biotype
2, discrimination of serovar E, the zoonotic serovar. The biotype 3 strains used
in this study were previously biotyped (11).
(ii) API 20E and API 20NE analysis. API 20E and API 20NE test kits
(bioMerieux) were used according to the manufacturer’s directions, with incu-
bation of the strips at 28°C. Bacterial suspensions in saline solution or in AUX
medium plus NaCl at a final concentration 1% (wt/vol) were used as the inocula
for API 20E and API 20NE kits, respectively (10). Examination of the strips was
conducted after 24 and 48 h. API profiles were compared using API DataBase
version 4.0 for API 20E strips and version 6.0 for API 20NE strips (APILAB
Software, version 3.3.3, Apilab Plus; bioMerieux).
(iii) BIOLOG analysis. BIOLOG-GN MicroPlates (BIOLOG) were used to
evaluate substrate utilization patterns of the strains. The cells were streaked on
BIOLOG Universal Growth agar (Oxoid) supplemented with 5% sheep eryth-
rocytes (BUG-S) and incubated for 24 h at 28°C. Wells of a plate were inoculated
with 150 l of bacterial suspensions adjusted to the appropriate density in saline
solution. The inoculated microplates were incubated at 28°C for 24 and 48 h and
analyzed using a BIOLOG Microstation reader. Test results were obtained and
identification (BIOLOG Microlog 6.01 database) was performed using BIOLOG
MicroLog 3 software (BIOLOG), applying the automatic threshold option. Dif-
ferences in the use of carbon substrates between the different groups were
analyzed using the chi-square test function at   0.05, employing SPSS 14.0 for
Windows. Bionumerics software version 4.0 (Applied Maths) was used to cluster
the strains based on their substrate utilization patterns using the unweighted-pair
group method using arithmetic average (UPGMA) and two different similarity
coefficients, the Jaccard and simple matching coefficients.
Genetic fingerprinting. (i) DNA sequence polymorphisms. The polymor-
phisms at selected loci were determined by PCR analysis of all V. vulnificus
strains. Differentiation between the described alleles of the hemolysin gene
(vvhA) and the 16S rRNA gene was performed under conditions described
elsewhere (35). vcg typing for the environmental (type E) or clinical (type C)
genotype was performed as described by Rosche et al. (33). In all assays, ca. 250
ng of DNA per 25 l of reaction mixture was amplified using the high-fidelity
Expand PCR system (Roche Diagnostics) in a TC-312 thermal cycler (Techne).
The existence of an association between polymorphism and group (biotype,
origin, or serovar) was calculated using the Pearson chi-square test function at
  0.05, employing SPSS 14.0 for Windows.
TABLE 1—Continued
Strain Origin
Country and
year of
isolation
Biotype Multiplexa
DNA polymorphismb
Ribogroup
(Rt)cvcg
type
vvhA
type
16S
rRNA
type
Profile
G83 Fish South Korea 1 BT1/3 E 1 B Atypical BII (25)
VV 352 Seawater United States 1 BT1/3 E 1 A Atypical BII (25)
MLT 406 Seawater United States 1 BT1/3 E 2 A 2 BII (26)
95-8-6 Diseased eel Denmark, 1995 2 BT2-nonSerE E 2 A 2 BII (26)
CECT 529T Human blood United States 1 BT1/3 E 1 A Atypical BII (26)
CECT 4174 Diseased eel Japan, 1979 2 BT2-SerE E 2 A 2 BII (27)
CG100 Oyster Taiwan, 1993 1 BT1/3 C 1 B 1 BII (28)
L49 Brackish water Japan 1 BT1/3 E 2 A 2 BII (29)
CECT 4607 Diseased eel Spain, 1992 2 BT2-SerE E 2 A 2 BII (30)
CECT 4999 Diseased eel Spain, 1999 2 BT2-SerE E 2 A 2 BII (30)
PD-2-66 Eel tank water Spain, 2003 1 BT1/3 E 2 B Atypical BII (30)
CECT 4601 Diseased eel Spain, 1989 2 BT2-SerE E 2 A 2 BII (31)
94-9-130 Seawater Denmark, 1994 1 BT1/3 E 2 A 2 BII (32)
CECT 7029 Diseased eel Denmark, 2004 2 BT2-nonSerE E 2 A 2 BII (32)
CECT 7030 Diseased eel Denmark, 2004 2 BT2-nonSerE E 2 A 2 BII (32)
95-8-162 Diseased eel Denmark, 1995 2 BT2-nonSerE E 2 A 2 BII (33)
CECT 4863 Leg wound United States 2 BT2-SerE E 2 A 2 BII (34)
CECT 897 Diseased eel Japan, 1979 2 BT2-SerE E 2 A 2 BII (35)
95-8-161 Diseased eel Denmark, 1995 2 BT2-nonSerE E 2 A 2 BII (36)
CECT 5343 Diseased eel Spain, 2000 2 BT2-nonSerE E 2 A 2 BII (36)
MLT404 Seawater United States 1 BT1/3 E 2 A 2 BII (37)
CECT 4865 Diseased shrimp Taiwan 2 BT2-SerE E 2 A 2 BII (38)
CECT 5139 Diseased eel Spain, 1998 2 BT2-SerE E 2 A 2 BII (38)
CECT 4866 Human blood Australia 2 BT2-SerE E 2 A 2 BII (39)
UE516 Diseased Japanese eel Taiwan 2 BT2-SerE E 2 A 2 BII (40)
94-9-118 Human disease Denmark, 1994 1 BT1/3 E 2 A 2 B (41)
534 Diseased eel Sweden 1 BT1/3 E 2 A 2 B (42)
PD-2-47 Eel tank water Spain, 2003 2 BT2-SerE E 2 A 2 BIII (43)
PD-2-51 Eel tank water Spain, 2003 2 BT2-SerE E 2 A 2 BIII (43)
CECT 5763 Eel tank water Spain, 2002 2 BT2-SerE E 2 A 2 BIII (44)
PD-2-50 Eel tank water Spain, 2003 2 BT2-SerE E 2 A 2 BIII (45)
PD-2-55 Eel tank water Spain, 2003 2 BT2-SerE E 2 A 2 BIII (45)
Riu-2 Seawater Spain, 2003 2 BT2-SerE E 2 A 2 BIII (46)
PD-2-56 Eel tank water Spain, 2003 2 BT2-SerE E 2 A 2 BIII (47)
CECT 5166 Wound infection United States 1 BT1/3 E 2 B Atypical NDd
a BT1/3, biotype 1 or 3; BT2-nonSerE, biotype 2 and not serovar E; BT2-SerE, biotype 2 serovar E.
b Results of the DNA polymorphism study (see Materials and Methods for details).
c See Fig. 2. Rt, ribopattern.
d ND, not determined.
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(ii) Automated ribotyping. Ribotyping of the V. vulnificus isolates was carried
out with the Riboprinter system (Qualicon Inc.). The assay was performed under
conditions recommended by the manufacturer using HindIII (Roche) at 400 U
l1. Riboprinter patterns were partially processed by the Riboprinter system
software in order to reduce background noise and to normalize the band posi-
tions using DNA size standards as references. The normalized patterns were
then exported for further analysis as .txt files and imported into the Bionumerics
software (version 4.0; Applied Maths) using LoadSamples script (DuPont Quali-
TABLE 2. Carbon sources used by V. vulnificus strains
Carbon source Type
Growtha
Species
(n  111)
Biotype 1
(n  51)
Biotype 2
Biotype 3
(n  5)Total
(n  55)
Serovar E
(n  36)
Non-serovar E
(n  19)
Dextrin Polymer      
Glycogen Polymer      
-D-Glucose Carbohydrate      
D-Trehalose Carbohydrate      
N-Acetyl-D-glucosamine Carbohydrate      
D-Fructose Carbohydrate      
L-Asparagine Amino acid      
Glucose 6-phosphate Phosphorylated
chemical
    () 
Tween 80 Polymer      ()
L-Glutamic acid Amino acid   () ()  
Inosine Aromatic chemical   () ()  
Maltose Carbohydrate () ()   () 
D-Gluconic acid Carboxylic acid ()  () ()  
Cellobioseb,c Carbohydrate () ()    
D-Mannose Carbohydrate () () () () () ()
Methylpyruvate Ester ()  () ()  ()
L-Aspartic acid Amino acid ()  () () () 
Gentiobioseb,c Carbohydrate () ()   () 
Tween 40 Polymer () () () () () 
Succinic acid Amide () () () () () 
Glucose 1-phosphate Phosphorylated
chemical
() () () () () ()
Monomethylsuccinate Ester () () V (73) V (69) () 
L-Alanylglycine Amino acid V (74) V (69) () () () V (60)
Glycyl-L-aspartic acidc Amino acid V (73) V (59) () () () ()
N-Acetyl-D-galactosamine Carbohydrate V (72) V (67) () V (72) () ()
Uridined Aromatic chemical V (72) () V (69) V (59) () ()
L-Alanine Amino acid V (66) V (63) V (69) V (72) V (63) V (60)
-Methyl-D-glucosideb,c Carbohydrate V (59) V (37) () () () 
DL-Lactic acidb,c,d Carboxylic acid V (59) V (73) V (44) V (33) V (63) ()
Glycerol Alcohol V (57) V (59) V (55) V (56) V (53) V (60)
D-Galactose Carbohydrate V (54) V (57) V (55) V (47) V (68) V (20)
Bromosuccinic acid Brominated
chemical
V (51) V (53) V (47) V (44) V (53) ()
DL--Glycerolphosphated Phosphorylated
chemical
V (48) V (49) V (46) V (56) V (26) V (60)
L-Proline Amino acid V (47) V (43) V (47) V (47) V (47) ()
Acetic acid Carboxylic acid V (38) V (45) V (35) V (36) V (32) 
L-Threonine Amino acid V (38) V (45) V (35) V (31) V (42) 
D-Mannitolc,d Carbohydrate V (36) V (39) V (36)  () 
D-Psicose Carbohydrate V (35) V (31) V (38) V (44) V (26) V (40)
L-Serineb Amino acid V (34) V (43) V (29) V (28) V (32) 
D-Glucuronic acidd Carboxylic acid V (33) V (28) V (38) V (28) V (58) V (40)
-Ketoglutaric acidd Carboxylic acid V (32) V (39) V (27) V (22) V (37) 
Glucuronamide Amide V (32) V (29) V (33) V (25) V (47) V (40)
Glycyl-L-glutamic acid Amino acid V (32) V (28) V (35) V (33) V (37) V (40)
-D-Lactoseb,c Carbohydrate V (31) V (16) V (47) V (50) V (43) 
Thymidineb,c Aromatic chemical V (31) V (41) V (18)  V (32) V (60)
Alaninamide Amide  V (22) V (22)  V (37) 
-Hydroxyphenylacetic acid Carboxylic acid  V (25) V (16) V (22)  
D-Alanine Amino acid  VV (22)   V (16) 
Propionic acidb Carboxylic acid   V (20) V (19) V (21) 
a , positive reaction for 90% of the isolates; (), positive reaction for 75 to 89% of the isolates; V, positive reaction for 11 to 74% of the isolates (the number
in parentheses is the percentage of positive isolates); , positive reaction for 10% of the isolates.
b Carbon source for which there are significant statistical differences (P  0.05) in its use between the three biotypes.
c Carbon source for which there are significant statistical differences (P  0.05) in its use between the four groups (biotype 1, biotype 2 serovar E, biotype 2
non-serovar E, and biotype 3).
d Carbon source for which there are significant statistical differences (P  0.05) in its use between the serovar E isolates and the rest of the biotype 2 isolates.
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FIG. 1. Dendrograms based on UPGMA analysis of the BIOLOG results obtained for the V. vulnificus collection using the Jaccard (A) or
simple matching (B) similarity coefficient. The scale bars indicate the percentage of dissimilarity. Biotype 1 strains are indicated by open ellipses,
biotype 2 serovar E strains are indicated by open rectangles, biotype 2 non-serovar E strains are indicated by filled rectangles, and biotype 3 strains
are indicated by open diamonds.
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con). Clustering analysis was performed by UPGMA based on the Dice coeffi-
cient for band matching, with a position tolerance and an optimization setting of
1%. Bands for band matching were assigned automatically and manually edited
if necessary.
RESULTS
Phenotypic analysis. (i) API 20E and API 20NE analysis. A
total of 25 different API 20E and API 20NE profiles were
obtained for the V. vulnificus collection (see Tables S1 and S2
in the supplemental material). In the case of the API 20E
system, only 60% of the strains were correctly identified as V.
vulnificus, and the percentage was 20% for biotype 3 isolates.
The remaining strains gave a mixed profile or were misidenti-
fied as Burkholderia cepacia or Vibrio parahaemolyticus. Three
main profiles were detected for biotype 1 isolates (5346105
[19.6%], 5146105 [15.7%], and 5346005 [17.6%]), two main
profiles were detected for biotype 2 serovar E isolates (5006005
[29.4%] and 5206005 [23.5%]), two main profiles were de-
tected for biotype 2 non-serovar E isolates (5146105 [38%] and
5346105 [33%]), and one main profile was detected for biotype
3 isolates (4146004 [40%]) (see Table S1 in the supplemental
material). None of the strains was correctly identified as V.
vulnificus with the API 20NE system. Instead, most of the
isolates were identified at the genus level as Aeromonas or
Vibrio, and the species Aeromonas hydrophila and Vibrio chol-
erae were the most frequent options (see Table S2 in the
supplemental material). The main profile exhibited by biotype
1 isolates was 7476745 (43.1%), the main profile exhibited
biotype 2 serovar E isolates was 5472745 (73.6%), the main
profile exhibited by biotype 2 non-serovar E isolates was
7476745 (61.9%), and the main profile exhibited by biotype 3
strains was 7062745 (40%).
(ii) BIOLOG GN2 plates. The BIOLOG system correctly
identified 84% of the 111 isolates studied. Eight of the low-
discrimination identifications (7% of the strains) were listed as
V. vulnificus as the first option, although with low probability.
The carbon sources that V. vulnificus was able to oxidize are
shown in Table 2. On average, 32 carbon substrates were uti-
lized. V. vulnificus strains did not use amines or carboxylic
acids, with the exception of D-glucoronic and succinic acid,
which were metabolized by more than the 80% of the strains
examined (Table 2). There was no specific profile (expressed as
the carbon sources utilized by an isolate) that could be as-
signed to a particular group of strains. In fact, only two strains,
isolated from the same water sample (PD-1 and PD-5), used
the same carbon sources. In addition, cluster analysis per-
formed by applying either the Jaccard index, which takes into
account the similarity based on the number of positive coinci-
dences, or simple matching, which takes into account the pos-
itive and negative coincidences, revealed that most of the
groups of strains were not related to a common biotype, sero-
var, or origin (Fig. 1). Such variability in the use of carbon
sources caused difficulties in attempts to establish a reliable
test that could be used for discriminating biotypes or serovars.
Nevertheless, we found statistical differences for the differen-
tial use of some carbon sources between groups (Table 2).
Some examples are the use of the cellobiose and gentibiose,
which was negative for the biotype 3 isolates but positive for
the rest of the strains tested. The biotype 2 strains were able to
oxidize -methyl-D-glucoside; however, no biotype 3 and few
biotype 1 isolates were able to use this carbon source.
Genetic diversity observed with DNA polymorphism locus
typing. Results of the multiplex PCR (34) analysis are shown in
Table 1. The allelic distribution among environmental, human,
and fish V. vulnificus isolates for the three biotypes is shown in
Table 3. Biotype 1 strains from oysters and human blood pre-
dominantly were vcg type C, whereas the biotype 1 strains from
fish and nonsepticemic human infections and most of the bio-
type 1 isolates from water, together with biotype 2 and 3
isolates regardless of their origin, were vcg type E. We detected
vvhA gene type 1 in biotype 1 strains from oysters and human
septicemia together with biotype 3 strains from human bacte-
remia, whereas biotype 1 strains from fish and human wounds
and all biotype 2 strains, irrespective of their origin, were vvhA
type 2. In contrast to the vcg results, we observed more vari-
ability in the vvhA typing results with the water isolates of
biotype 1. These isolates, together with those from human
wounds, also showed variable results for the 16S rRNA gene
TABLE 3. Distribution of genotypes and genotypic profiles among V. vulnificus biotypes according to strain origin
Biotype Origin n
% with genotypea: % with genotypic profileb:
vcg
type C
vcg
type E
vvh
type 1
vvh
type 2
rRNA
type A
rRNA
type B
rRNA
type AB 1 2 3 Atypical
1 Water 19 21 79 26 74 68 26 5 21 63 0 16
Oyster 8 75 25 87 13 13 87 0 75 0 0 25
Fish 6 0 100 17 83 83 17 0 0 83 0 17
Human blood 12 83 17 83 17 17 83 0 75 8 0 16
Human (not blood) 4 0 100 0 100 50 50 0 0 50 0 50
2 Water 10 0 100 0 100 100 0 0 0 100 0 0
Healthy fish 2 0 100 0 100 100 0 0 0 100 0 0
Diseased fish 38 0 100 0 100 100 0 0 0 100 0 0
Diseased shrimp 1 0 100 0 100 100 0 0 0 100 0 0
Human blood 2 0 100 0 100 100 0 0 0 100 0 0
Human (not blood) 2 0 100 0 100 100 0 0 0 100 0 0
3 Bacteremia 5 0 100 100 0 0 0 100 0 0 100 0
a Percentage of isolates with positive PCR results.
b Percentage of isolates with each profile. See the text for a description of the profiles.
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polymorphisms, while fish biotype 1 and biotype 2 isolates,
regardless of their origin, were type A. Oyster and human
blood biotype 1 isolates were type B, and biotype 3 isolates
were type AB. Thus, three main genotypic profiles were found
among the collection of V. vulnificus isolates. Profile 1 con-
sisted of genotype vcg type C, 16S rRNA type B, and vvh type
1 and was exhibited by biotype 1 strains from human septice-
mia and oysters. Profile 2 consisted of genotype vcg type E, 16S
rRNA type A, and vvh type 2 and was exhibited by biotype 2
isolates, regardless of their origin, and by biotype 1 isolates
from fish and water and some human isolates. Profile 3 con-
sisted of genotype vcg type E, 16S rRNA type AB, and vvh type
2 and was exhibited only by biotype 3 strains. No specific
profile was found for water and human nonblood isolates of
biotype 1, which showed variable results. Some atypical profiles
were also found, such as the profile showed by environmental
biotype 1 isolate Riu-1, which was positive for both types of
16S rRNA (as were the biotype 3 strains) and possessed
hemolysin type 2.
Automated ribotyping. Figure 2 shows the dendrogram ob-
tained from the normalized ribotypes (Rt) after UPGMA clus-
tering. The Riboprinter generated some bands with low inten-
sity, especially above 15 kb, that probably corresponded to
undigested DNA as they were not reproducible when selected
strains were ribotyped a second time. These bands, together
with those at 1 kb, were not taken into account in the ri-
botyping cluster analysis. Forty-seven Rt were distinguished
among the 111 V. vulnificus strains (Table 1), which grouped at
a similarity level of 62%. We included two strains of other
Vibrio species as outgroups, V. harveyi and V. parahaemolyticus,
which were clearly different from the strains of V. vulnificus
and which grouped at 45% similarity (Fig. 2). Two main groups
of V. vulnificus strains could be distinguished. Division A in-
cluded 92% of the biotype 1 strains and the majority of human
blood (70%) and oyster (75%) isolates with profile 1, whereas
division B included some biotype 1 strains from human
wounds, fish, and water with profile 2 and the majority of
biotype 2 (96%) and 3 (100%) isolates with profiles 2 and 3,
respectively. These two divisions could be subdivided into five
groups (ribogroups AI, AII, BI, BII, and BIII) based on80%
similarity, even though five strains (CECT 4869, CG106, V4,
94-9-118, and 534) did not cluster with other strains (Fig. 2).
All of the strains with profile 1 were clustered in ribogroups AI
and AII, except for a strain from human septicemia (CECT
5169) and an environmental strain (CG100). Ribogroups AI,
AII, and BIII included strains with a unique biotype; ribo-
groups AI and AII included biotype 1 strains, mostly from
humans, and ribogroup BIII included biotype 2 and serovar E
strains isolated from an unusual source, brackish water of the
estuary of the River Ebro (Mediterranean Sea). The rest of the
biotype 2 strains were included in ribogroup BII, and most of
them exhibited the same Rt pattern (Rt 25) regardless of the
serovar, while all the strains of biotype 3 were grouped in
ribogroup BI, which also showed a unique Rt (Rt 24).
DISCUSSION
In order to validate the genotyping systems designed for
differentiating clinical from environmental V. vulnificus iso-
lates, a selection of these systems was used with a large collec-
tion of strains of different biotypes and serovars recovered
from sources worldwide. The phenotypic diversity of the col-
lection was analyzed first with three miniaturized bacterial
identification systems, whose usefulness for identification of V.
vulnificus at the specific or intraspecific level was evaluated in
parallel. The BIOLOG system was the most effective system,
giving 84% correctly identified strains. The BIOLOG results
showed that V. vulnificus has the ability to oxidize a great
variety of carbon sources. This species is also highly heteroge-
neous, since almost every isolate had a unique profile. The
percentage of correctly identified strains was 60% when the
API 20E system was used and 0% with the API 20NE system.
These results are in agreement with previous reports on the
doubtful usefulness of both API systems for identification of
clinical and environmental V. vulnificus isolates (10, 17, 18, 29),
although they are still being used, mostly for clinical diagnosis.
Based on these results, the BIOLOG system is the most ade-
quate system for V. vulnificus identification at the species level,
and the other two systems, especially the API 20NE system,
should not be used unless the databases are updated with the
profiles found in the present work. When the utility of the
three systems for intraspecific classification was considered,
none of them was able to distinguish biotype 2 non-serovar E
(serovar A/I) isolates from biotype 1 isolates, although several
API 20E and API 20NE profiles were found to be specific for
biotype 2 serovar E and biotype 3 strains (see Tables S1 and S2
in the supplemental material). Inclusion of these profiles in the
API database would facilitate correct identification of more V.
vulnificus isolates and in some cases subclassification into bio-
type 2 serovar E or biotype 3. In general, however, the profiles
would not allow discrimination of other biotypes or groups.
Despite finding several tests in the BIOLOG system that re-
vealed significant differences between groups, we found that
using these tests was not adequate for good discrimination.
Only the combination of negative results for cellobiose and
gentibiose breakdown allowed allocation of isolates to bio-
type 3.
Previous studies have proposed various genetic methods to
distinguish strains of this species with human-pathogenic po-
tential (14, 28, 33, 35). We performed an analysis of three of
these methods, the 16S rRNA, vvhA, and vcg methods, with
our V. vulnificus collection. According to previous reports,
most V. vulnificus human isolates should be vcg type C, vvhA
type 1, and 16S rRNA type B (genotypic profile 1 in our study),
and most environmental isolates should be vcg type E, vvhA
type 2, and 16S rRNA type A (genotypic profile 2 in our study).
However, we were able to establish an association only be-
tween genotypic profile 1 and human isolates for biotype 1
strains from septicemic cases, regardless of their geographical
origin. The remaining biotype 1 human isolates mostly exhib-
ited genotype profile 2, like the majority of the environmental
biotype 1 isolates, except those from oysters. Our results for
oyster isolates are opposite the results obtained by other work-
ers (22, 28, 33) and could be due to the inclusion of isolates
from Asia, where a major proportion of 16S rRNA type B has
been reported (25). In previous studies variation between ra-
tios of 16S rRNA type A to rRNA type B were observed for
different sampling points or water temperatures (22, 27, 39).
For the rest of the isolates, we found an association between
profile and biotype rather than an association between profile
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FIG. 2. Dendrogram based on UPGMA cluster analysis of the ribotypes obtained in this study. The scale bar indicates the percentage of
dissimilarity. Divisions A and B and the five ribogroups are shown. The symbols are the same as those used in Fig. 1.
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and origin of the isolate. Thus, all biotype 2 strains, regardless
of their source (human, fish, or water), exhibited profile 2, and
all biotype 3 strains, all from human bacteremia, exhibited
profile 3. The variability in profiles observed among biotype 1
strains can be attributed to the greater genetic variability of
this biotype. Genetic characterization of our V. vulnificus col-
lection performed by ribotyping confirmed this observation.
Ribotyping is a general technique also used in epidemiological
studies of V. vulnificus (3, 5, 6, 9, 19, 23). We selected HindIII
to perform the DNA digestion since it has been reported to
provide the best discrimination between biotypes (9, 18). A
common pattern was observed for all V. vulnificus strains, and
a group of bands between 2 and 3 kb was absent in the profiles
of the other vibrios examined. These bands were also observed
in previous studies with manual protocols (9, 18, 22). The
strains were grouped on the basis of their similarities in ri-
bopatterns into two divisions and five groups. As expected,
biotype 1 strains were found in almost every group and sub-
group. Nevertheless, the biotype 1 strains that exhibited profile
1 were located mostly in division A, while the second division
included all the biotype 2 and 3 strains together with additional
biotype 1 strains from environmental sources and wound in-
fections. In this division, the major genotypic profiles were
profiles 2 and 3. Interestingly, ribogroup BI was comprised of
all biotype 3 isolates that were closely related to environmental
biotype 1 strains from sites related to fish farms. This result
supports the previous hypothesis concerning the origin of bio-
type 3 as a clone associated with tilapia culture in Israel that
recently emerged (13).
The eel-pathogenic strains were located in division B, with a
major Rt (Rt 25) that included strains of the different serovars
as well as other biotype 1 strains isolated mainly from the
environment or from human wounds. This result also supports
the hypothesis that biotype 2 strains could have been emerged
from biotype 1 strains present in the environment. Recently, it
has been shown that eel virulence relies on a 68-kb plasmid
that can be transmitted between strains by conjugation with the
aid of a conjugative plasmid (26). In this scenario, biotype 2
strains could have evolved independently by acquisition of the
virulence plasmid by different clones of biotype 1 strains in the
environment. Only one of these clones (serovar E) could be
phenotypically distinguished from the rest of the biotypes,
while the rest (serovars A and I) could not be distinguished.
Additional studies based on multilocus sequence analysis
with biotype 2 strains of different serovars and from different
sources are needed to confirm this hypothesis.
Ribotyping has been used for differentiating clinical and
environmental V. vulnificus isolates and biotypes, and several
correlations between ribopatterns and geographic origin have
been found (5, 6, 8). Our results, however, suggest that this
technique may be useful for revealing genetic relationships
among V. vulnificus isolates, but it is not likely to be useful for
rapid identification of strains with public health interest.
In conclusion, the results obtained in the present work dem-
onstrate that the species V. vulnificus is highly heterogeneous
and that most of the diversity is present in biotype 1. Biotype
2 and 3 strains, in contrast, are more homogeneous, even
though biotype 2 is serologically and phenotypically heteroge-
neous. There is a need for methods capable of rapid, sensitive,
and accurate identification of the strains dangerous for public
health. The DNA polymorphisms studied have been proposed
for routine monitoring of the quality of seafood and water, but
our results suggest that their use could eliminate samples con-
taining strains with human-pathogenic potential, such as bio-
type 2 serovar E and biotype 3 strains. It is clear, therefore,
that new genetic markers with epidemiological potential need
to be found to clearly differentiate V. vulnificus.
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